Dimerix Limited

Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammation-related conditions with significant unmet medical needs. Leveraging a proprietary receptor technology platform, Dimerix advances drug candidates such as DMX-200 for rare kidney diseases like focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease, as well as DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Melbourne and operates globally, targeting both rare and widespread health challenges. Dimerix’s research-driven approach spans early discovery through to commercialization, with several candidates in advanced clinical trials. Its scalable platform enables rapid identification and development of new pharmaceutical products, positioning Dimerix as a key player in the biotechnology sector. The company’s shares are traded on the CHI-X Market Australia – Limit Venue, providing investors access to a dynamic segment of the healthcare industry.